Cover Image

Transdermal Nicotine Patch Increases the Number and Function of Endothelial Progenitor Cells in Young Healthy Nonsmokers without Adverse Hemodynamic Effects

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Yen‐Yu Liu, Ting‐Yi Tien, Chung‐Lieh Hung, Yih‐Jer Wu, Cheng‐Huang Su, Hung‐I Yeh
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Clinical Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Letter: Methodological Considerations in Comparing Liver Outcomes of Glucagon‐Like Peptide‐1 Receptor and Sodium Glucose Cotransporter‐2 Inhibitors
by: Cheng‐Hsien Hung, et al.
Published: (2025)

Clinical Outcomes in Type 2 Diabetes Patients After Acute Myocardial Infarction: A Comparison of Sodium–Glucose Cotransporter 2 Inhibitors vs. Non‐Users
by: Hsin‐Fu Lee, et al.
Published: (2024)

Advanced Fibrosis and Cardiometabolic Risk Burden Increase Major Cardiovascular Events in Chronic Hepatitis C Patients With Steatotic Liver Disease After Viral Eradication
by: Pei‐Chien Tsai, et al.
Published: (2025)

Editorial: Genotyping for Hepatocellular Carcinoma Risk Stratification in the General Population. Authors' Reply
by: Daniel Q. Huang, et al.
Published: (2026)

Pharmacokinetic Evaluation of a Cinnamon Product on CYP2A6 Substrate Drugs: Application of a Novel Tool Involving the Nicotine Metabolite Ratio
by: Aiden‐Hung P. Nguyen, et al.
Published: (2026)

Letter: Crohn's Disease or Comorbidity? Reassessing Opioid Prescribing Patterns
by: Kuan‐Ju Lin, et al.
Published: (2025)

Therapeutic Strategies of Denosumab Sequential Therapy: A Four‐Armed Randomized Controlled Trial
by: Hung‐Kuan Yen, et al.
Published: (2025)

Research Communication: Risk of Tuberculosis With Advanced Therapies in 20,705 Patients With Inflammatory Bowel Diseases in Low Incidence Regions—A U.S. Claims‐Based Study
by: Dhruv Ahuja, et al.
Published: (2025)

Long‐Term Outcomes of an Infliximab‐First Versus Vedolizumab‐First Treatment Strategy in Biologic‐Naïve Patients With Ulcerative Colitis
by: Austin Haynesworth, et al.
Published: (2024)

Air Pollution Associated With Mortality Among Chronic Hepatitis B Patients Treated With Nucleotide/Nucleoside Analogues
by: Tyng‐Yuan Jang, et al.
Published: (2025)

Pharmacokinetics of Intravenous and Transdermal Flunixin Meglumine in Wool and Hair Sheep ( Ovis aries )
by: Kaitlyn G. Forrest, et al.
Published: (2025)

Discovering Severe Adverse Reactions From Pharmacokinetic Drug–Drug Interactions Through Literature Analysis and Electronic Health Record Verification
by: Eugene Jeong, et al.
Published: (2024)

Pharmacokinetic Parameters of Oral Firocoxib, Oral Meloxicam, and Transdermal Flunixin in Meat Type Goats
by: Mikaela M. Weeder, et al.
Published: (2025)

The Persistent Ambiguity of Adverse Drug Reactions
by: Edward M. Sellers, et al.
Published: (2025)

Letter: Dynamic HBcrAg and HBsAg After Nucleos(t)ide Analogue Cessation: Considerations in Interpreting Predictive Performance
by: Hsiang‐Ting Keng, et al.
Published: (2026)

Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection
by: Yu‐Ping Chang, et al.
Published: (2025)

Pharmacokinetics of Moxidectin in Bare‐Nosed Wombats ( Vombatus ursinus ) After Intravenous, Sub‐Cutaneous and Transdermal Administration
by: E. K. Stott, et al.
Published: (2026)

Ticagrelor versus Adjusted‐Dose Prasugrel in Acute Coronary Syndrome with Percutaneous Coronary Intervention
by: Ming‐Lung Tsai, et al.
Published: (2024)

Population Pharmacokinetics of siRNA JNJ ‐73763989 in Healthy Participants and Patients With Chronic Hepatitis B
by: Tetsuro Ogawa, et al.
Published: (2025)

Overall and Comparative Risk of Shingles With Advanced Therapies in Patients With Inflammatory Bowel Diseases
by: Dhruv Ahuja, et al.
Published: (2025)

Letters on “Efficacy and Safety of Tenofovir Alafenamide ( TAF ) and Tenofovir Disoproxil Fumarate ( TDF ) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment.” Authors' Reply
by: Grace Lai‐Hung Wong, et al.
Published: (2025)

Major Adverse Cardiac Events with Ondansetron: A Systematic Review
by: Michael Cristian Garcia, et al.
Published: (2025)

Pharmacokinetics, Mass Balance, Safety, and Tolerability of Obeldesivir in Healthy Participants
by: Olena Anoshchenko, et al.
Published: (2024)

Editorial: Combination Therapies for MASH : A Step Forward or More Complexity?
by: Xiao‐Dong Zhou, et al.
Published: (2025)

PNPLA3 Genotype and Clinical Factors Impact Hepatocellular Carcinoma Risk: Findings From a Prospective Cohort Study
by: Daniel Q. Huang, et al.
Published: (2026)

The Burden of Adverse Drug Reactions in Africa in the Context of Pharmacogenetics‐Based Clinical Guidelines
by: Janine Scholefield, et al.
Published: (2026)

FDA Adverse Event Reporting System Essentials: A Reflection on Study Conception
by: Emanuel Raschi, et al.
Published: (2025)

Editorial: Revisit the causes and long‐term outcomes in cirrhosis patients
by: Ming‐Lun Yeh, et al.
Published: (2024)

Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease
by: Pamela Navarro‐Gonzales, et al.
Published: (2024)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease
by: Cong Dai, et al.
Published: (2024)

Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease
Published: (2024)

Urinary Kidney Injury Biomarker Profiles in Healthy Individuals and After Nephrotoxic and Ischemic Injury
by: Sushrut S. Waikar, et al.
Published: (2025)

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis
by: Yee Hui Yeo, et al.
Published: (2026)

Liver Fibrosis and the Risk of Coronary Artery Disease, Stent Thrombosis, Restenosis and Adverse Clinical Outcomes
by: Na Tian, et al.
Published: (2025)

Association of Pregabalin vs. Duloxetine with Cardiovascular Events: A Retrospective Cohort Study Among US Veterans With Chronic Musculoskeletal Pain
by: Sachalee Campbell, et al.
Published: (2026)

Pharmacokinetics of the Monoclonal Antibody, Sotrovimab, in Healthy Participants Following IM Administration at Different Injection Sites
by: Asma El‐Zailik, et al.
Published: (2024)

Phenoconversion Due to Drug–Drug Interactions in CYP2C19 Genotyped Healthy Volunteers
by: Kenza Abouir, et al.
Published: (2024)

Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non‐Liver Malignancies in Hepatitis B Endemic Areas
by: Yi‐Ping Hung, et al.
Published: (2024)

Letter: Optimising Prevention of Adverse Events and Antiviral Prophylaxis for HBV ‐Infected HCC Patients Undergoing Immunotherapy
by: Jialing Wang, et al.
Published: (2025)

Mild Endoscopic Disease Activity Is Associated With Adverse Outcomes Among Older Adults With Inflammatory Bowel Disease
by: Catherine Z. Tang, et al.
Published: (2025)